knowledge -WSS

knowledge

author：knowledge 2025-09-28 21:57:41 - browse：56

Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a handful of biotech companies are trying to develop next-generation, longer-lasting therapies based on a very different approach: RNA interference.

This Nobel Prize-winning science works by degrading the biological blueprints that RNA use to make proteins — without the genetic instructions, the troublesome proteins are never made and the gene is essentially muted.

If the companies succeed, it would be a significant shift in the obesity treatment revolution, away from weekly drugs targeting hormones to medications that could be given much less frequently — twice a year or even less — and pinpoint genetic contributors to weight.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： In key trial, Verve's treatment lowers cholesterol levels in patients

hotspot

WSS

Lilly’s weekly insulin works as well as daily products, new studies show

A daunting task: navigating dual Medicare, Medicaid eligibility

Boston hospital trains restaurant workers on naloxone for overdoses

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

HHS suspends federal funding for EcoHealth Alliance

The United States must get value

leisure time

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

How to save PrEP access — and even expand it

Free medical tuition alone isn't enough to close gaps in primary care

Dobbs anniversary: the lost opportunity of abortion as health care

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Bright Health sells Medicare Advantage business to Molina

Hospitals look to new technology to keep health care workers safe

Hollywood unions extend contract negotiations for actors

Abbott's new stent may help patients with peripheral artery disease

How one medical school became remarkably diverse

Fertility clinic egg and embryo storage is a disaster

explore

The United States must get value

Free medical tuition alone isn't enough to close gaps in primary care

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

As H5N1 spreads in cows, experts warn against drinking raw milk

World's first CRISPR

U.K. considers world's first use of meningitis vaccine to address gonorrhea

hotspot

hotspot

entertainment

entertainment